Disease relapse following high-dose chemotherapy and autologous stem cell transplant (ASCT) remains the principal cause of mortality in patients with relapsed or refractory lymphomas. In an effort to prevent post-ASCT relapse, a number of studies have evaluated the role of maintenance therapy with varying success. In diffuse large B-cell lymphoma, studies evaluating maintenance rituximab (MR) following ASCT failed to demonstrate improved outcomes. In follicular lymphoma, MR was associated with an improvement in PFS; however, no overall survival (OS) benefit was noted. Emerging data evaluating MR in mantle cell lymphoma (MCL) have demonstrated improvements in PFS, although a consistent improvement in OS has yet to be demonstrated. Given the aggressive and incurable nature of MCL, it is prudent for practitioners to weigh the risks and benefits of MR in the post-ASCT setting. Similarly, post-ASCT maintenance therapy with brentuximab vedotin in Hodgkin lymphoma, has led to improved PFS and may be considered in those with a high risk of relapse. Ongoing clinical studies evaluating a multitude of novel maintenance therapies are crucial to the efforts of further defining and optimizing the role of post-transplant maintenance therapy in lymphoma. (2018) 53, 11-21; doi:10.1038/bmt.2017.196; published online 2 October 2017 INTRODUCTION High-dose chemotherapy followed by autologous stem cell transplant (ASCT) is an established approach for the treatment of chemotherapy-sensitive relapsed and refractory lymphomas.
INTRODUCTION
High-dose chemotherapy followed by autologous stem cell transplant (ASCT) is an established approach for the treatment of chemotherapy-sensitive relapsed and refractory lymphomas. [1] [2] [3] Frequently, the aim of this treatment is either curative (in aggressive lymphoma subtypes) or for improved disease control (in indolent lymphomas). The efficacy and durability of this approach is dependent on a number of factors including histologic subtype, remission status before ASCT, number of prior lines of therapy and the presence of other high-risk features. [4] [5] [6] Relapse or progression following ASCT is the leading cause of treatment failure and death in patients. 4, 7, 8 Disease resurgence following ASCT is thought to arise from resistant minimal residual disease, contamination of the stem cell product with malignant cells or failure of the immune system to eradicate tumor cells. 9 Consequently, preventing relapse or progression following ASCT represents a key area of need. Since the adoption of high-dose chemotherapy and ASCT, a number of studies have investigated the use of maintenance therapies post ASCT with the aim of reducing relapse rates and improving outcomes.
When evaluating maintenance therapies, a number of factors must be considered. The ideal maintenance therapy should be active against the underlying disease, be associated with minimal toxicity and be relatively convenient to administer. One must recognize that by utilizing maintenance therapy in every patient, practitioners will be inherently overtreating many patients who may otherwise remain in remission after transplant. In light of this notion, it is crucial that the maintenance therapy be associated with an improvement in outcomes or quality of life to justify the cost, logistical concerns and potential toxicity encountered. Herein, we review the clinical data for post-ASCT maintenance therapy in both Hodgkin and non-Hodgkin lymphoma (NHL), and provide an overview of innovative therapies currently in clinical trials in this setting.
DIFFUSE LARGE B-CELL LYMPHOMA
For patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), high-dose chemotherapy followed by ASCT remains the standard of care. Despite this approach, nearly 40-60% of patients suffer disease relapse following ASCT with dismal outcomes. 1 Given this poor prognosis, attempts to prevent early treatment failure with maintenance therapy have been explored. Table 1 summarizes the clinical studies evaluating maintenance therapies following ASCT in DLBCL.
One of the first single-arm studies to evaluate post-ASCT maintenance therapy in high-risk DLBCL by Zhang et al. 10 utilized in vivo rituximab purging followed by maintenance rituximab (MR) given every 3 months for a total of two years post ASCT. At a median follow-up of 44 months, this approach demonstrated an 83% PFS and 100% overall survival (OS). Tsirigotis et al. 11 retrospectively evaluated the role of MR following ASCT in 93 patients with relapsed or refractory aggressive B-cell NHL. The authors sought to compare outcomes between those managed with observation and those treated with either single-agent MR or MR in combination with cytokine therapy. PFS and OS were 19 and 42 months, respectively, in the observation group and not reached in the maintenance cohort, although the median followup was~24 months. and prednisone) or AC (doxorubicin and cyclophosphamide)/ACE (doxorubicin, cyclophosphamide and etoposide) induction therapy followed by high-dose chemotherapy and ASCT. Patients demonstrating at least a partial response (PR) to ASCT were then randomized to 4 weekly doses of rituximab (375 mg/m 2 ) or observation. At a median of 4 years of follow-up from posttransplant randomization, there was no improvement in eventfree survival (EFS) or OS in the MR arm compared with the observation arm. However, in a planned subgroup analysis of patients achieving a complete response (CR) following ASCT, those randomized to MR demonstrated a significantly higher EFS compared with observation (86% vs 68%; P = 0.023). 12 Although this subgroup analysis suggests a potential benefit for MR, it should be emphasized that this study employed autologous transplant in the upfront setting, which is not standard of care. Furthermore, the omission of rituximab as part of intial treatment and the use of a non-standard induction chemotherapy regimen significantly limits the generalizability of these findings.
In the phase III CORAL study, patients with relapsed or refractory DLBCL were allocated to one of two salvage chemotherapy regimens. Those responding to therapy subsequently underwent high-dose chemotherapy followed by ASCT. Following transplant, patients were again randomized to either MR (375 mg/m 2 every 2 months for six doses) or observation. This study failed to demonstrate an improvement in 4-year EFS (52% vs 53%) or OS (61% vs 65%) in the MR arm compared with observation. In addition to its lack of benefit, MR was associated with increased toxicity compared to observation (30% vs 17%), with more serious adverse events noted. 13 Recent attempts have explored other therapeutic platforms with the goal of mitigating relapse and extending remission durations following ASCT. Advances in our understanding of tumor biology and immune evasion have led to the development of therapies aimed at unleashing the immune system on malignant cells. The interaction between the programmed death-1 (PD-1) receptor on T cells and the PD ligand 1 (PD-L1) results in downregulation of T-cell function and represents an important pathway of immune tolerance in the setting of an inflammatory response. Frequently, hematologic malignancies exploit this pathway in order to evade immune attack and thus recent efforts have focused on therapeutic targeting of the PD-1 pathway in the clinical setting. 14, 15 Shortly after ASCT, there are increased circulating populations of PD-1 expressing cells, including CD45R0+ effector/memory T cells, natural killer cells and monocytes, which are integral in immune reconstitution. 14, 15 It was hypothesized that PD-1 blockade in this setting would limit tumor driven lymphocyte exhaustion via the PD-1 pathway and potentially lead to improvement in outcomes through eradication of residual disease. In a prospective, phase II study, the anti-PD-1 monoclonal antibody, pidilizumab was administered every 42 days for three cycles following ASCT in patients with relapsed/refractory DLBCL, primary mediastinal B-cell lymphoma or transformed indolent B-cell lymphoma. The 16-month PFS and OS from the start of first treatment was 72% and 85%, respectively. Of particular note, in the subgroup of patients with measurable disease post ASCT, pidilizumab was associated with an overall response rate (ORR) of 51% with 34% achieving a CR by computed tomography (CT) criteria. Overall, the therapy was well tolerated without report of significant autoimmune toxicity and no infusion reactions or treatment-related mortality. 16 Although these findings have yet to be confirmed in larger randomized studies, therapy with checkpoint inhibitors such as pidilizumab shows promise in the post-ASCT setting in DLBCL, and is the subject of active clinical studies.
Despite encouraging retrospective and phase II data utilizing MR, phase III studies have highlighted the significant toxicity burden and overall mixed outcomes in terms of EFS with this approach. Although a promising option, currently MR post ASCT is 17 Given this limitation, initial efforts focused on utilizing maintenance therapy to prolong remissions after front-line therapy or relapse. In the phase III PRIMA study, patients with advanced FL who achieved a response to frontline immunochemotherapy were then randomized to MR (375 mg/m 2 every 8 weeks for 2 years) or observation. With a median follow-up of 3 years, PFS was 75% in the MR arm compared with 58% in the observation arm; yet, there was no significant difference in OS (P = 0.60). 18 Similarly, van Oers et al. 19 explored the role of MR in relapsed and refractory FL and demonstrated superior median PFS in the MR arm compared with observation (3.7 years vs 1.3 years). Based on promising results with the use of MR in the upfront and relapsed setting, maintenance therapy approaches have been further explored in the post-ASCT setting. Table 2 summarizes the clinical studies evaluating maintenance therapies following ASCT in FL.
Small single-arm studies in the pre-rituximab era suggest that MR following ASCT is associated with improved PFS. In a study by Brugger et al., 20 20 patients with advanced-stage FL were treated with 4 weekly doses of rituximab (375 mg/m 2 ) as a consolidation strategy following ASCT. The authors reported an EFS rate of 88% at 60 months post-ASCT; however, the small sample size should be considered. In another study by Hicks et al., 21 patients with relapsed FL were treated with high-dose chemotherapy followed by ASCT with in vivo rituximab graft purging. At 2 and 6 months post transplant, patients received 4 weekly courses of MR therapy (375 mg/m 2 ). This study demonstrated a 5-year PFS of 59% with a 5-year OS of 78%. 21 Post-ASCT MR was explored in a randomized phase III study by Pettengell et al. 22 In this study, 280 rituximab-naive patients with chemosensitive, relapsed FL were randomized to pre-transplant rituximab purging or observation. Following transplant, patients were randomized to observation or MR (375 mg/m 2 every 2 months for a total of four infusions). Unfortunately, rituximab in vivo purging failed to improve 10-year PFS when compared with observation (48.6% vs 42%; P = 0.18). Although post-ASCT MR therapy was associated with significantly higher 10-year PFS (54% vs 37%; P = 0.012), no difference in OS was seen between the arms (73.1% vs 67.8%; P = NS). In addition, MR therapy was associated with a nonstatistically significant increase in neutropenia in the first year of therapy. 22 Of particular note, in this study MR was provided for only four total doses compared with the more widely adopted 2-year schedule often utilized in the non-transplant setting, potentially negating an OS benefit. Based on the lack of benefit in OS seen in this large phase III study, MR has not been widely adopted following ASCT in FL.
Despite encouraging data from preliminary studies using maintenance therapy post-ASCT in FL, phase III data revealed a PFS, but no OS benefit. It should be noted that lack of a potential OS benefit may be a consequence of the abbreviated rituximab administration schedule, although no data exist to substantiate this claim. Ideally, future clinical trials will help to better define the role of MR as post-ASCT therapy in FL.
MANTLE CELL LYMPHOMA
Mantle cell lymphoma (MCL) is an aggressive subtype of NHL and is generally considered incurable, even despite intensive therapeutic approaches. 23 It is characterized by the t(11:14) chromosomal translocation which results in dysregulation and overexpression of the cell cycle protein cyclin D1. 24 MCL accounts for~5-10% of NHL cases and has been increasing in incidence in the past two decades. 25 Although several studies utilizing induction chemotherapy followed by ASCT have demonstrated significant improvement in PFS and OS, there is a continuous pattern of relapse following ASCT. 26 Relapse after ASCT has been associated with an OS of approximately only 2 years. [27] [28] [29] The use of MR following induction rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy remains an effective strategy to improve OS in elderly, nontransplanted patients with MCL. Consequently, recent efforts have evaluated the role of rituximab maintenance therapy post ASCT.
30 Table 3 summarizes the clinical studies evaluating maintenance therapies following ASCT in MCL.
Dietrich et al. 31 retrospectively compared MR (375 mg/m 2 every 3 months for 2 years) with observation following high-dose chemotherapy therapy and ASCT. On multivariate analysis, MR therapy was associated with improved PFS (hazard ratio (HR) = 0.23; 95% confidence interval (CI) = 0.06-0.80), although no OS benefit was noted (HR = 0.61, 95% CI = 0.14-2.65). 31 Graf et al. Recently, prospective studies have further investigated the role of maintenance therapy post ASCT in MCL. In the LYMA study, patients who achieved a PR or CR to high-dose chemotherapy followed by ASCT were randomized to either observation or MR (375 mg/m 2 every 2 months for 3 years). With a median follow-up of 50.2 months, patients randomized to the MR arm demonstrated a significantly improved 4-year EFS (78.9% vs 61.4%; P = 0.001) and 4-year OS (88.7% vs 81.4%; P = 0.041) compared with observation. 33 In a large randomized trial, the CALGB 50403 study investigated the efficacy of bortezomib therapy post ASCT. Patients were treated with an R-CHOP based induction regimen along with methotrexate, followed by chemomobilization with etoposide, cytarabine and rituximab before receiving high-dose chemotherapy and ASCT. Following ASCT, patients were randomized to either bortezomib maintenance therapy (1.6 mg/m 2 on days 1, 8, 15 and 22 of an 8-week cycle for a total of 10 cycles) or bortezomib consolidation therapy (1.3 mg/m 2 on days 1, 4, 8 and 11 of a 3-week cycle for a total of 4 cycles). The 5-year PFS for the bortezomib maintenance arm was 70% versus 69% in the bortezomib consolidation arm, suggesting similar efficacy. Unfortunately, bortezomib consolidation was associated with more patient withdrawals, as a consequence of mainly peripheral neuropathy and cytopenias. The authors compared the results of this study with a historical control, the CALGB 59909 study, which utilized the same treatment backbone, with the exception of bortezomib, post-ASCT therapy. In this comparison, the 5-year PFS from the time of transplantation was 72.7% for CALGB 50403 study versus 51.5% for the CALGB 59909 study, suggesting a significant benefit for the addition of bortezomib post ASCT. 34 In MCL, minimal residual disease status has been identified as a relevant marker of outcomes and remission duration. 35, 36 Recent efforts have focused on utilizing minimal residual disease monitoring to better identify patients at high-risk for relapse. In the Nordic MCL-2 study, PCR-based minimal residual disease testing was employed in 78 patients, of which 74 were in a clinical CR following ASCT. Thirty-six of the 74 patients eventually developed molecular relapse and, of those, 26 received preemptive rituximab (375 mg/m 2 weekly for 4 weeks). Pre-emptive therapy resulted in a second molecular remission in 92% of patients with a median molecular relapse-free survival of 1.5 years. 37 Although minimal residual disease-based pre-emptive therapy represents a more personalized treatment approach, randomized data are needed before this practice can be recommended. In MCL, maintenance therapy post ASCT has gained considerable interest in recent years as a consequence of mounting retrospective and prospective data. A PFS benefit for MR has been reproducible through these various studies, though no firm conclusions can be drawn regarding an OS advantage. [31] [32] [33] Given the aggressive and incurable nature of MCL, it is important that practitioners weigh the risks and benefits of post-ASCT MR therapy. One must consider the toxicities associated with these maintenance regimens, along with the increased cost and other logistical concerns. At the present time, post-ASCT MR is an acceptable standard of care in MCL. Post-ASCT bortezomib, although associated with an improvement in PFS, comes at the cost of significant toxicity including peripheral neuropathy and cytopenias, and therefore this approach is seldom utilized. Mature follow-up from ongoing clinical studies, along with further randomized prospective data, will help further assess toxicity and the impact of maintenance therapy post ASCT on OS.
HODGKIN LYMPHOMA
In the United States, standard therapy for Hodgkin lymphoma (HL) frequently includes ABVD (adriamycin, bleomycin, vinblastine and dacarbazine)-based chemotherapy, which results in a long-term PFS for 60-80% of patients. 38 In patients with relapsed or refractory disease, salvage chemotherapy followed by high-dose chemotherapy and ASCT is considered standard of care, based on improvement in PFS compared with conventional chemotherapy alone. 2, 3 With this treatment approach,~50% of patients relapse following ASCT, with poor long-term OS. 39, 40 With the aim of improving outcomes following ASCT in HL, maintenance strategies have demonstrated varying success (Table 4) . In a phase III, multicenter study by Nagler et al., 41 HL patients were randomized to maintenance therapy with interleukin-2 and interferon-α, versus observation following high-dose chemotherapy and ASCT. This approach yielded similar OS (89% vs 86%; P = 0.9) in the two arms and no significant difference in DFS or relapse rate was found. 41 Similarly, Bosly et al. 42 evaluated interferon-2b maintenance therapy versus observation in 54 patients with relapsed HL following treatment with high-dose chemotherapy and ASCT. In this analysis, no EFS or OS differences were noted between the maintenance and observation arms. 42 Histone deacetylases are important in a number of subtypes of lymphoma through their interaction with cell cycle progression, along with cytokine and chemokine signaling. 43, 44 Panobinostat is a pan-histone deacetylase inhibitor and was found to have activity in HL, including an ORR of 27% (23% PR and 4% CR) in a phase II study. 45 Based on this data, panobinostat was investigated as consolidation therapy in the post-ASCT setting. In the PATH study, patients with at least one of the following risk factors: primary refractory disease, early disease relapse (o 12 months), history of multiple relapses, stage II or IV disease or hemoglobin o10.5 g/dL at relapse before ASCT were randomized to receive panobinostat (45 mg orally 3 times a week, every other week) or placebo. Unfortunately, due to slow accrual, the study was terminated early, and no formal efficacy evaluation was performed. Although small patient numbers, panobinostat consolidation appeared to be well tolerated. Owing to disease progression, more patients discontinued therapy in the placebo arm than the panobinostat arm.
46
CD30 is a unique marker that is highly expressed on malignant Hodgkin/Reed-Sternberg cells and recently has been effectively targeted with the antibody-drug conjugate brentuximab vedotin (BV). BV is an anti-CD30 antibody, which is conjugated to monomethyl auristatin E, a microtubule-disrupting agent. Upon binding to the CD30 receptor, the antibody-drug conjugate is internalized. Through proteolytic cleavage, the monomethyl auristatin E payload is released and subsequently binds tubulin, leading to cell cycle arrest and apoptosis. 47, 48 In a phase II study of single-agent BV in patients with relapsed or refractory disease after ASCT, the ORR was 75% with 34% of patients achieving a CR. Furthermore, BV therapy was well tolerated in this population with adverse events such as peripheral neuropathy, neutropenia, fatigue and diarrhea. 49 In 2011, BV was Food and Drug Administration approved for the treatment of HL after failure of ASCT or at least two prior multi-agent chemotherapy regimens.
The role of BV maintenance therapy was recently explored in the AETHERA trial. In this study, patients with relapsed/refractory HL who demonstrated a CR, PR, or stable disease to pretransplantation salvage chemotherapy underwent high-dose conditioning therapy and ASCT. They were then randomized to maintenance BV (1.8 mg/kg) or placebo every 3 weeks for up to 16 cycles. Eligible patients included those with risk factors for progression following ASCT including: primary refractory disease, relapsed HL with an initial remission duration less than 12 months or the presence of extranodal involvement before pretransplantation salvage chemotherapy. Of note, patients with prior BV exposure were excluded from the study. This treatment approach yielded a median PFS of 43 months in the BV arm compared to 24 months with placebo. Although longer term follow-up is needed, it appears that BV reduces the risk of progression or death by 50% (HR = 0.50; 95% CI = 0.36-0.70) in the post-ASCT setting. Furthermore, on prespecified subgroup analysis, BV therapy was shown to reduce the risk of progression across all subgroups. Common toxicities in the BV arm included peripheral sensory neuropathy (56% in BV arm vs 16% in placebo) and neutropenia (35% in BV arm vs 12% in placebo). 50 Based on the results of this study, BV was approved for post-ASCT consolidation therapy in HL patients at high risk for relapse or progression.
Although many maintenance strategies have been explored in HL, consolidation BV therapy has been the only treatment associated with improved outcomes in patients with high risk of relapse following ASCT. Following publication of the AETHERA study and subsequent Food and Drug Administration approval, post-ASCT BV therapy has been increasingly adopted in the clinical setting. When considering this approach, it is crucial for practitioners to correctly identify patients at high risk for disease progression. Although generally well tolerated, BV therapy is associated with sensory peripheral neuropathy and neutropenia, and close monitoring is required to screen for adverse events. In addition, in the AETHERA study, patients with prior BV exposure were excluded and therefore the utility of BV consolidation therapy post-ASCT in this population is unclear. Lastly, in this study, patients who progressed in the placebo arm were able to crossover to BV therapy as part of a separate clinical study and therefore an OS benefit of consolidation therapy remains unknown at this time. 50 
FUTURE DIRECTIONS
In an effort to further improve outcomes and limit relapse following ASCT, recent clinical trials have focused on incorporating novel agents into post-ASCT maintenance therapy. Based on a more complete understanding of the underlying disease biology, many innovative therapies have been investigated in the relapsed and refractory setting with encouraging activity and an acceptable safety profile. The following section details some of the novel therapeutic approaches in lymphoma and provides a framework for understanding their incorporation in maintenance therapy. Table 5 summarizes the current clinical studies evaluating novel agents as maintenance therapy following ASCT. Immunomodulators Diffuse large B-cell lymphoma. Lenalidomide is an immunomodulatory agent that has shown both antitumor and antiproliferative activity in various subtypes of NHL. 51 In relapsed/refractory DLBCL, lenalidomide has been associated with response rates ranging from 19 to 28%. 52, 53 When evaluating the activity based on cell of origin, lenalidomide was found to have an ORR of 53% in the non-germinal center subtype versus 9% in the germinal center subtype of DLBCL. 54 This work provided the foundation for further phase II studies combining lenalidomide with R-CHOP therapy in the upfront treatment of DLBCL, yielding promising results. 55, 56 In the international, phase III, double-blind REMARC study, elderly (age 60-80 years) patients with untreated DLBCL, who responded to R-CHOP therapy, were randomized to either 24 months of lenalidomide (25 mg on days 1-21 of a 28 day cycle) or placebo. With a median follow-up of 40 months, the median PFS was not reached in the lenalidomide arm versus 68 months in the placebo arm (HR = 0.708, 95% CI = 0.537-0.932). Despite these encouraging results, no OS benefit was seen with lenalidomide maintenance therapy (HR = 1.218, 95% CI = 0.861-1.721). 57 Dean et al. 58 prospectively evaluated lenalidomide and rituximab maintenance therapy post ASCT in B-cell NHL, including three patients with DLBCL. In the phase I study, patients were treated with escalating doses of lenalidomide (days 1-21 of a 28-day cycle) with rituximab (375 mg/m 2 ) provided on day 1 of every other cycle. The study closed prematurely mainly due to hematologic toxicity; however, therapy was initiated at a median of 93 days post-ASCT, which may have accounted for its poor tolerance. 58 Single-agent lenalidomide is currently being evaluated as maintenance therapy post ASCT in a phase I/II study (NCT01575860).
Follicular lymphoma. In the NHL-001 study, single-agent lenalidomide was employed in relapsed/refractory FL and demonstrated an ORR of 27%, with responders demonstrating prolonged disease control with a median duration of response > 16.5 months. 59 The role of lenalidomide in the post-transplant setting is currently being investigated in a phase I/II study (NCT01575860).
Mantle cell lymphoma. Previous studies with single-agent lenalidomide in relapsed/refractory MCL yielded a 26% ORR, leading to its approval in MCL. 60 When lenalidomide was combined with rituximab, the combination yielded an ORR of 57% with a median response duration of 18.9 months. 61 This combination was recently trialed in the upfront setting in MCL and was associated with an ORR of 87% (CR rate of 61%) and an impressive 2-year PFS of 85%. Common toxicities included nausea, edema, fatigue, fever and grade 3/4 adverse events including neutropenia, thrombocytopenia and rash. 62 In MCL, lenalidomide maintenance therapy following ASCT is currently being explored in two trials (NCT02354313 and NCT01575860).
Hodgkin lymphoma. In a multicenter, phase II study, lenalidomide demonstrated an ORR of 19% in heavily pretreated patients with relapsed/refractory HL. This therapy was generally well tolerated, with mainly grade 3/4 hematologic toxicity including neutropenia (47%), anemia (29%) and thrombocytopenia (18%). 63 Based on these results, two studies are currently underway to investigate the role of lenalidomide as maintenance therapy in the post-ASCT setting (NCT01207921 and NCT01575860).
Bruton's tyrosine kinase inhibitors
Diffuse large B-cell lymphoma. B-cell receptor (BCR) signaling has been recognized as a key growth pathway in B-cell malignancies. Within this pathway, Bruton's tyrosine kinase is an essential enzyme which interacts with nuclear factor-κB, ultimately leading to proliferation and survival. 64 In the activated B-cell-like (ABC) subtype of DLBCL, mutations targeting the BCR pathway result in chronic active BCR signaling. Recent efforts have focused on pharmacological inhibition of many key enzymes in this pathway. 65 In ABC subtype DLBCL, ibrutinib, an irreversible Bruton's tyrosine kinase inhibitor, demonstrated an ORR of 40% compared with 5% in patients with the germinal center B-cell subtype. 66 Based on these encouraging results, a current Alliance/ BMT CTN phase III study is investigating the use of ibrutinib or placebo during conditioning therapy followed by ASCT with a second allocation to 12 months of maintenance ibrutinib or placebo in patients with the ABC subtype of DLBCL (NCT02443077).
Mantle cell lymphoma. Similarly, in MCL, dysregulated signaling through the BCR has been shown to contribute to tumor growth and survival. Consequently, treatment approaches have been developed to target the constitutive activation of the BCR signaling pathway. In a multicenter phase II study by Wang et al., 67 patients with relapsed/refractory MCL treated with single-agent ibrutinib showed an ORR of 68%, with 21% demonstrating a CR. Owing to its activity in the relapsed and refractory setting, ibrutinib is currently being explored as posttransplant maintenance therapy in two prospective clinical studies (NCT02242097 and NCT02858258).
Proteasome inhibitors
Diffuse large B-cell lymphoma. As mentioned, constitutive activation of the nuclear factor-κB pathway is a key feature in the ABC subtype of DLBCL and has been associated with an inferior prognosis. Several potential inhibitors of nuclear factor-κB have been investigated with the hope of improving outcomes. 68 In a phase I/II study by Ruan et al., 69 patients with untreated DLBCL and adverse prognostic factors were treated with R-CHOP plus bortezomib and demonstrated an ORR of 100% with a 2-year PFS of 64%. Of particular importance, germinal center B-cell and ABC/ Non-germinal center B-cell subtypes of DLBCL demonstrated similar outcomes, suggesting that bortezomib may mitigate the adverse prognosis of the ABC subtype. 69 These results prompted three randomized studies evaluating the addition of bortezomib to chemotherapy. In the REMoDL-B study, newly diagnosed DLBCL patients were treated with one cycle of R-CHOP therapy while concurrently undergoing cell of origin testing. Before the second cycle of therapy, patients were then randomized to R-CHOP or R-CHOP + bortezomib. With a median of 16 months' follow-up, the authors demonstrated no improvement in PFS (78% vs 82%, P = 0.611) with the addition of bortezomib to chemotherapy. 70 Similarly, in the LYM-2034 study, Offner et al. 71 found no improvement in PFS or OS with the addition of bortezomib to chemotherapy.
Likewise, in the phase II pyramid study, untreated patients with Non-germinal center B-cell DLBCL were randomized to R-CHOP or R-CHOP+bortezomib with the primary endpoint of PFS. With a median follow-up of 31.5 months, there was no improvement in PFS or OS with the addition of bortezomib. 72 Although these randomized studies failed to show a benefit for the addition of bortezomib, this may potentially be explained by selection bias, differences in cell of origin testing and suboptimal chemotherapy dosing (as in the LYM-2034 trial). Although disappointing, these results have not precluded further studies of bortezomib in the maintenance setting. A current phase II study is evaluating the combination of bortezomib and the histone deacetylase inhibitor, vorinostat following ASCT in DLBCL (NCT00992446).
Follicular lymphoma. As in DLBCL, constitutive activation of the nuclear factor-κB pathway has been implicated in the pathogenesis of FL, providing a rationale for investigating proteasome inhibition. 73 In a phase II study by Ribrag et al. 74 twice-weekly versus once-weekly dosing of single-agent bortezomib were compared in relapsed/refractory FL. In this study, twice-weekly dosing yielded an ORR of 32%, compared with 22% in the onceweekly schedule. The treatment was generally well tolerated with mostly hematologic toxicity seen. 74 Further studies evaluating the combination of bortezomib and rituximab have also demonstrated promising results. 75, 76 A current phase II study is investigating the role of maintenance therapy with bortezomib in combination with vorinostat in FL following ASCT (NCT00992446).
Mantle cell lymphoma. Bortezomib was Food and Drug Administration approved for patients with relapsed/refractory MCL following the PINNACLE study by Fisher et al., 77 which demonstrated an ORR of 33%, with a median duration of response of 9.2 months. Further studies have explored bortezomib in combination with systemic chemotherapy, along with other targeted therapies, both in the frontline and relapsed/refractory setting. [78] [79] [80] Currently, bortezomib is being investigated as post-ASCT maintenance therapy in three clinical studies (NCT02632396, NCT00992446 and NCT01267812).
Checkpoint inhibitors
Diffuse large B-cell lymphoma. Tumor cells may exploit the PD-1 pathway in an attempt to avoid immune surveillance. PD-L1 expression has been noted in a subset of DLBCL, leading to inhibition of tumor-associated T cells. 81, 82 Encouraging results from PD-1 targeting with the pidilizumab in the post-ASCT setting have paved the way for further evaluation of checkpoint blockade in DLBCL. 16 A phase II study utilizing pembrolizumab in the post-ASCT maintenance setting is currently underway (NCT02362997).
Hodgkin lymphoma. In HL, there is overexpression of PD-L1 on Hodgkin/Reed-Sternberg cells, suggesting a mechanism for evading the immune system through a dampening of active T-cell tumor immune surveillance. 83 Nivolumab is an anti-PD-1 monoclonal antibody that binds to the PD-1 receptor on T cells, preventing it's interaction with PD-L1 and PD-L2 on Hodgkin/ Reed-Sternberg cells. In a phase I study, single-agent nivolumab was associated with an ORR of 87% (CR rate 17%, PR rate 70%) 84 . Based on this data, nivolumab was granted accelerated approval in 2016 for the treatment of HL in patients who relapsed or progressed following ASCT and post-transplantation BV. In addition, pembrolizumab, another anti-PD-1 monoclonal antibody, has demonstrated activity in relapsed/refractory HL with an ORR of 65% with 16% of patients achieving a CR. 85 Based on the encouraging activity of checkpoint inhibitors, clinical studies are underway to evaluate the efficacy of checkpoint blockade post ASCT in HL (NCT02362997).
mTOR inhibitors
Diffuse large B-cell lymphoma. The mammalian target of rapamycin (mTOR) protein has a key role in the phosphatidylinositol-3-kinase/Akt signaling pathway, which is integral in multiple cellular functions including proliferation, cell cycle progression and autophagy. 86, 87 Aberrant activation of the phosphatidylinositol-3-kinase/Akt/mTOR pathway is common in DLBCL and has been shown to result in loss of PTEN, and constitutive activation of other upstream pathways. 88 In preclinical models, the mTOR inhibitor, everolimus, was found to promote G1 cell cycle arrest and enhance the cytotoxicity of rituximab. 89, 90 Another mTOR inhibitor, temsirolimus, was trialed in relapsed DLBCL and resulted in an ORR of 28%, although the median PFS was only 2.6 months. 91 Similarly, everolimus, demonstrated an ORR of 30% in relapsed DLBCL in a phase II study by Witzig et al. 92 In the post-ASCT setting, mTOR inhibition with temsirolimus is currently being evaluated in combination with rituximab (NCT01665768).
Mantle cell lymphoma. The phosphatidylinositol-3-kinase/Akt/ mTOR pathway appears to be crucial for MCL pathogenesis as a consequence of its effect on both cellular growth and mRNA regulation of the cell cycle protein cyclin D1. 93, 94 In MCL cell lines, both temsirolimus and everolimus have been shown to inhibit tumor proliferation. 95, 96 In the largest phase III study to date, two dosing schedules of temsirolimus were compared to investigator's choice in relapsed/refractory MCL. In this study, the 175/75 mg arm was found to be superior to investigator's choice yielding an ORR of 22 versus 2%. As seen in previous studies, grade 3-4 hematologic toxicity was the most frequent adverse event. 97 In MCL, post-ASCT maintenance therapy with temsirolimus and rituximab is currently being evaluated in a phase II study (NCT01665768).
Hodgkin lymphoma. Prior studies have demonstrated Akt phosphorylation and activation in both HL cell line and HL tumor biopsies, suggesting the importance of the phosphatidylinositol-3-kinase/Akt/mTOR axis in the pathogenesis of HL. 98, 99 Inhibition of the mTOR pathway was noted to promote G1-S cell cycle arrest and to enhance the activity of doxorubicin in Hodgkin/ReedSternberg cell lines. 100 Based on this preclinical data, everolimus was evaluated in relapsed/refractory HL, demonstrating an ORR of 47%. Despite this activity, everolimus was associated with significant toxicity, including 74% of patients experiencing grade 3-4 adverse events. 101 In the previously referenced study, NCT01665768, temsirolimus is being trialed as post-ASCT maintenance therapy in HL.
Anti-CD20 monoclonal antibodies Mantle cell lymphoma. Anti-CD20 monoclonal antibody therapy has led to significant improvement in outcomes in MCL. 28 Rituximab is a chimeric anti-CD20 monoclonal antibody; it's mechanism relies primarily on antibody-dependent cellular cytotoxicity and complement-mediated cytotoxicity. Recently, efforts to improve on its immunogenic potential through glycoengineering have resulted in newer compounds such as obinutuzumab, which is thought to demonstrate more potent antibody-dependent cellular cytotoxicity. 102 In a phase III, openlabel study, the combination of rituximab and chlorambucil was compared with obinutuzumab and chlorambucil in patients with untreated CLL. In this study, the combination of obinutuzumab and chlorambucil proved superior, with a higher CR rate (20.7% vs 7%) and a longer median PFS (26.7 months vs 11.1 months). 103 These results serve as the basis for the incorporation of newer anti-CD20 monoclonal antibodies into traditional treatment platforms with the hope of improving outcomes. Specifically, obinutuzumab is being evaluated in a phase II study as part of both induction and post-ASCT maintenance therapy in MCL (NCT02896582).
Chimeric antigen receptor T cells
Diffuse large B-cell lymphoma. Chimeric antigen receptor T cells (CAR T cells) are T cells genetically engineered to express a chimeric antigen receptor, consisting of an extracellular antigenbinding region or ligand to a transmembrane spanning and intracellular signaling domain. 104 Currently, CD19 directed CAR T cells have been investigated in a number of clinical studies with encouraging safety and efficacy. In one of the initial studies by Kochenderfer et al., 105 patients with advanced B-cell malignancy, including nine patients with DLBCL, were treated with fludarabine and cyclophosphamide conditioning therapy followed by CD19 CAR T-cell infusion. Although small numbers, eight patients achieved a CR, including four of seven evaluable patients with chemotherapy-refractory DLBCL. Toxicities included cytokine release syndrome and neurotoxicity, although largely resolved by 3 weeks following CAR T-cell infusion. 105 Based on these results, a number of multicenter studies are underway to further evaluate the safety and efficacy of CAR T-cell therapy in B-cell malignancies. Specifically, CAR T-cell therapy is being investigated in the maintenance setting following ASCT in patients with DLBCL (NCT01840566).
Hodgkin lymphoma. Based on its expression pattern, CD30 represents a promising therapeutic target in HL. In a phase I study utilizing a CD30 CAR T-cell in relapsed/refractory HL, 39% of patients demonstrated a PR with 33% achieving stable disease. Overall, the therapy was well tolerated with grade ⩾ 3 toxicity reported in only 11% of patients. 106 Further studies are underway to evaluate CD30 directed CAR-T cell therapy in the relapsed setting, as well as maintenance following ASCT in HL and CD30+ aggressive lymphomas (NCT01316146).
Summary. Relapse following ASCT remains the principal cause of mortality in patients with relapsed/refractory HL and NHL. A variety of approaches have been explored in order to mitigate this risk, including maintenance therapy post-ASCT. In DLBCL and FL, these efforts have yielded promising improvements in EFS, yet no OS benefit has been demonstrated. Maintenance therapy with rituximab in MCL and BV in HL have resulted in improved outcomes and these strategies are increasingly employed in the clinical setting.
Encouragingly, a number of currently enrolling clinical studies are evaluating rationally designed, novel targeted and cellular therapies in the post-ASCT maintenance setting. A more thorough understanding of the molecular basis of lymphoma will be integral in developing future maintenance strategies aimed at maintaining remissions following ASCT. Although many agents have shown promise in small, early phase clinical trials, it will be crucial to investigate these treatments in a randomized fashion in order to better evaluate benefit. Moving forward, research efforts should similarly focus on more precise identification of patients at high risk of relapse or progression, and employing maintenance therapies in this select population.
